FTC ok for modified final order for Hikma buy of Ben Venue assets

1 April 2016

The Federal Trade Commission has approved a modified final order settling charges that Jordon-headquartered Hikma Pharmaceuticals’ (LSE: HIK) acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, a unit of Boehringer Ingelheim, was anticompetitive (The Pharma Letter February 21).

Under the terms of the settlement, Hikma is required to divest assets related to five generic injectable drugs to Amphastar Pharmaceuticals, a California-based specialty pharmaceutical company that sells generic injectable and inhalation products.

Because Hikma and Amphastar adjusted the price that Amphastar paid for the divested assets after the Commission had accepted the consent agreement for public comment, the consent order has been modified to incorporate the revised divestiture agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK